Investors
Partner with us to set the new standard
What we offer
- A publication-backed enzymatic bioconjugation technology originating at Max Planck, supported by two patent families.
- Applications in protein conjugation, detection and immobilization, with research kits advancing toward commercial launch.
- A business model combining research products, technology licensing and application-focused development partnerships.
- Opportunities to extend Connectase into biotechnology platforms and therapeutic applications through partnered development.
How we work together
- We introduce our team, technology, commercial strategy and upcoming milestones.
- Where there is mutual interest, we share further information and discuss the investment opportunity.
- Together, we explore the potential fit, timing and value of your strategic involvement.
Learn more
More on working with investors
Connectase is preparing to translate an established scientific technology with proof of concept into a commercial biotechnology company. Developed at Max Planck and supported by public research and technology-transfer programs, the technology has demonstrated applications in protein conjugation, detection and immobilization.
Our initial commercial focus is on launching research kits, establishing industry partnerships and generating revenue through product sales, licensing and services. This business should quickly become self-sustaining and allow us to build increasing evidence toward our longer-term ambition: to establish Connectase as a leading technology for therapeutic conjugation. We pursue opportunities to enable targeted drug delivery with an advanced ability to equip active substances with ligands. These range from antibody-drug conjugates (ADCs) to nanoparticle delivery of active substances, including nucleic acids. Connectase offers multiple conjugation sites with controlled stoichiometry and orientation, giving clean, homogeneous and scalable conjugates. We develop applications, establish regulatory requirements and advance the technology toward clinical and commercial use.
As we prepare for company formation and seed financing, we welcome investors who share our ambitions and can contribute experience, network and strategic support alongside capital.